ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
- SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company's potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for ALX2004 following clearance of the Investigational New Drug application from the U.S. Food and Drug Administration earlier this year.
- 05/13/2025
|
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on ALX2004 research program on May 20 Company will not pursue U.S. registrational path in gastric cancer following receipt of FDA feedback that accelerated approval pathway is not feasible based on ASPEN-06 due to standard-of-care evolving to ENHERTU® Data milestones expected across Company's three clinical programs in 2026 Cash runway has been extended into Q4 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.
- 05/08/2025
|
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
- SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open.
- 05/02/2025
|
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
- - Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R 2 ) was well-tolerated and demonstrated promising anti-tumor activity
- 04/25/2025
|
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
- SOUTH SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced topline data from its Phase 2 ASPEN-03 and ASPEN-04 clinical trials. The company's investigational CD47-blocker evorpacept, when added to Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) with or without chemotherapy, did not meet the primary endpoints in the ASPEN-03 and ASPEN-04 trials of improved objective response rates (ORR) as compared to historical controls of pembrolizumab alone and pembrolizumab with chemotherapy, respectively, as a first-line treatment in patients with advanced head and neck squamous cell carcinoma (HNSCC). The combination of evorpacept and pembrolizumab with or without chemotherapy in ASPEN-03 and ASPEN-04 demonstrated a manageable safety profile and was consistent with what has been previously reported for pembrolizumab and chemotherapy in this setting. Although the company will no longer pursue evorpacept in combination with pembrolizumab in HNSCC, multiple clinical trials of evorpacept in combination with anti-cancer antibodies will continue based on established proof-of-concept.
- 04/25/2025
|
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
- ALX Oncology Holdings (ALXO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- 03/20/2025
|
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- – Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI
- 03/06/2025
|
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
- Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and colorectal cancers Advancing novel EGFR-targeted antibody-drug conjugate (ADC) candidate, ALX2004, into clinical-stage development with IND submission planned for Q1 2025 Company implements strategic prioritization, resource optimizations and reductions to extend cash runway into Q4 2026 Webcast featuring company leadership and external key opinion leaders to take place today at 6:00 a.m. PT/9:00 a.m.
- 03/05/2025
|
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
- SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open.
- 02/27/2025
|
ALX Oncology to Host Virtual R&D Day on March 5, 2025
- SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m.
- 02/18/2025
|
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
- SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, announced positive updated data from the ASPEN-06 Phase 2 clinical trial demonstrating that the company's investigational CD47-blocker evorpacept generates a durable clinical response with a well-tolerated safety profile among patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The updated results, which build upon previously announced topline results, will be shared today in an oral presentation (Abstract #332) at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco.
- 01/23/2025
|
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
- SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that effective January 21, 2025, the Compensation Committee of the Board of Directors of ALX Oncology granted an inducement stock option to purchase a total of 600,000 shares of ALX Oncology's common stock to Harish Shantharam, the Company's Chief Financial Officer, in connection with the commencement of his employment. Mr. Shantharam's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and were granted as inducements material to Mr. Shantharam to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
- 01/22/2025
|
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
- SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that the company will host a virtual event on Thursday, January 23, at 1:00 p.m. PT/4:00 p.m. ET to discuss updated data from the ASPEN-06 Phase 2 clinical trial evaluating the company's investigational CD47-blocker evorpacept in patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.
- 01/21/2025
|
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
- Here is how ALX Oncology Holdings Inc. (ALXO) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year.
- 01/07/2025
|
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
- SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 - 25, 2025.
- 12/18/2024
|
ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- ALX Oncology Holdings (ALXO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 11/21/2024
|
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
- Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development
- 11/14/2024
|
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.
- 11/07/2024
|
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
- Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers
- 11/01/2024
|
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
- ALX Oncology's Evorpacept, a first-in-class CD47 inhibitor, shows promising results in cancer treatment with reduced side effects and a favorable safety profile. Evorpacept's combination with TRP demonstrated improved response rates and longer duration of response in HER2-positive gastric and GEJ cancer trials. The ASPEN-06 trial also showed favorable results, with a 40.3% ORR in HER2-positive gastric/GEJ cancer, higher than the control group's 26.6%.
- 09/11/2024
|
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
- - Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development - - Jaume Pons, Ph.D., and Sophia Randolph, M.D.
- 08/06/2024
|
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
- SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced topline data from its Phase 2 ASPEN-06 clinical trial. The trial demonstrated clinically meaningful improvements in overall response rate and duration of response among patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.
- 07/31/2024
|
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
- SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer.
- 07/31/2024
|
ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
- ALX Oncology valuation has dropped below $500 million, presenting new studies at venues like ASCO, reaching a point of inflection. Evorpacept is the main focus, showing promising activity signals in gastric cancer and urothelial carcinoma, with upcoming data updates and trials. Financially, ALXO has a reasonable cash pool to fund operations for the near term, with a runway of 5-6 quarters.
- 06/27/2024
|
Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround
- The heavy selling pressure might have exhausted for ALX Oncology Holdings (ALXO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 06/03/2024
|
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
- SOUTH SAN FRANCISCO, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented data from its Phase 1 ASPEN-07 clinical trial in a poster presentation (abstract #4575) at the 2024 American Society of Cancer Oncology (“ASCO”) Annual Meeting being held in Chicago from May 31-June 4, 2024. These findings represent the first evorpacept combination data with an ADC from ASPEN-07's ongoing, open-label, single-arm, clinical trial of evorpacept in combination with PADCEV (enfortumab vedotin or “EV”) in patients with locally advanced or metastatic urothelial cancer (“la/m UC”). Evorpacept is a CD47 blocker with an inactivated Fc effector domain that is designed to minimize associated toxicity.
- 06/02/2024
|
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management will participate in the Jefferies Global Healthcare Conference. Details are as follows:
- 05/29/2024
|
Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet
- The mean of analysts' price targets for ALX Oncology Holdings (ALXO) points to a 36.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 05/14/2024
|
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
- SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
- 05/09/2024
|
ALX Oncology Appoints Allison Dillon as Chief Business Officer
- SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer (“CBO”).
- 05/07/2024
|
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
- SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the acceptance of two abstracts for poster presentation at the American Society of Cancer Oncology (“ASCO”), which will be held in Chicago from May 31-June 4, 2024.
- 04/24/2024
|
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
- ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
- 04/11/2024
|
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
- – Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (“R2”)– Evorpacept plus R2 was well tolerated with a safety profile similar to historical R2 – The combination achieved promising initial activity with a best overall response rate (“ORR”) of 94% and a complete response rate (“CRR”) of 83% in patients with indolent R/R B-NHL (R2 historical CRR benchmark is 34%)
- 04/09/2024
|
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
- 03/07/2024
|
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
- - Investigator-initiated trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma selected for oral presentation
- 03/05/2024
|
7 Small-Cap Stocks That Wall Street Loves for Good Reason
- As we head into 2024, it's common for investors to look back on 2023. Much of this year had investors in a defensive posture.
- 12/22/2023
|
ALX Oncology shares jump 9% after Jefferies upgrade
- ALX Oncology Holdings Inc. shares ALXO, +9.73% climbed 9% premarket on Friday after Jefferies analysts upgraded the stock to buy, from hold. The stock is “very cheap,” the analysts wrote, given that the company is set to have results from three promising phase 2 trials in 2024.
- 12/08/2023
|
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
- 11/13/2023
|
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
- SOUTH SAN FRANCISCO, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants. ALX Oncology sold 8,663,793 shares of common stock, which included 1,293,103 shares of common stock pursuant to the full exercise of the underwriters' option to purchase additional shares and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,250,000 shares of common stock in the offering. The shares of common stock were sold at a public offering price of $6.38 per share, the closing price on October 4, 2023, and the pre-funded warrants were sold at a public offering price of $6.379 per pre-funded warrant. The gross proceeds to ALX Oncology from this offering were approximately $63.2 million, before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants were offered by the Company.
- 10/10/2023
|
ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept
- ALX Oncology reported positive interim results from its phase 2 study using its anti-CD47 drug for HER2-positive gastric/gastroesophageal junction cancer. Final results from the ASPEN-06 study are expected to be released in Q2 2024, potentially leading to further gains for investors. ALXO also announced a cash raise of $55 million, reducing the need for a future cash raise and lowering the risk of dilution.
- 10/09/2023
|
ALX Oncology Announces Pricing of Public Offering
- SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants. ALX Oncology is selling 7,370,690 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,250,000 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $6.38 per share, the closing price on October 4, 2023, and the pre-funded warrants are being sold at a public offering price of $6.379 per pre-funded warrant, which represents the per share public offering price for each common share less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to ALX Oncology from this offering are expected to be approximately $55.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering are being offered by the Company. In addition, ALX Oncology has granted the underwriters a 30-day option to purchase up to an additional 1,293,103 shares of its common stock at the public offering price per share less underwriting discounts and commissions. The offering is expected to close on or about October 10, 2023, subject to the satisfaction of customary closing conditions.
- 10/05/2023
|
ALX Oncology Announces Proposed Public Offering
- SOUTH SAN FRANCISCO, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants in this offering will be sold by ALX Oncology. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. ALX Oncology intends to use the net proceeds from the offering to fund ongoing development of evorpacept, including clinical trials targeting market expansion, and for working capital and general corporate purposes. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering, including shares of common stock underlying the pre-funded warrants.
- 10/04/2023
|
ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data
- Interim data from a mid-stage study shows that a combination regimen of ALX Oncology's (ALXO) lead candidate achieved 52% ORR in certain gastric cancer patients.
- 10/04/2023
|
Why ALX Oncology Stock Is Skyrocketing Today
- ALX Oncology reported positive interim results from a phase 2 study of a combo drug featuring evorpacept. Evorpacept showed great potential in treating gastric/gastroesophageal junction cancer.
- 10/03/2023
|
ALX Oncology stock doubles on early data from phase II cancer trial
- ALX Oncology Holdings Inc saw its stock value double in pre-market trading on the heels of promising interim data from a phase II study assessing the potential of its lead asset in cancer of the stomach and esophagus. The ASPEN-06 clinical evaluated the effectiveness of evorpacept in treating patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer.
- 10/03/2023
|
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
- -- Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors
- 10/03/2023
|
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
- SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the hosting of an investor call and webcast on Tuesday, October 3rd at 8:00 AM EDT to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of advanced HER2-positive gastric cancer.
- 10/02/2023
|
ALX Oncology Announces September Investor Conference Participation
- SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences.
- 08/31/2023
|
ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
- ALX Oncology Holdings Inc. (ALXO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 08/10/2023
|
ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 at 10:30 am PT at the Westin St. Francis in San Francisco.
- 01/03/2023
|
ALX Oncology Announces Upcoming Investor Conference Participation
- SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in four upcoming investor conferences.
- 11/02/2022
|
ALX Oncology Announces Upcoming Investor Conference Participation
- SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences.
- 09/01/2022
|
ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC
- The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.
- 01/28/2022
|
New Strong Sell Stocks for January 19th
- ONEM, ALXO, and AVNS have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2022
- 01/19/2022
|
ALX Oncology Stock (ALXO): Why The Price Fell
- The stock price of ALX Oncology Holdings Inc (NASDAQ: ALXO) fell by 24.2% in the most recent trading session. This is why it happened.
- 12/14/2021
|
ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation
- ALX Oncology Holdings Inc (NASDAQ: ALXO) presented initial clinical data from its ongoing Phase 1 / 2 trial evaluating evorpacept combined with azacitidine for untreated higher-risk or relapsed or refractory myelodysplastic syndrome. The new results were shared at the 63rd American Society of Hematology (ASH).
- 12/13/2021
|
ALX Oncology Stock: Attractive After Recent Data And Slump In Price
- ALX Oncology is developing a novel CD47 inhibitor and has differentiated itself from its competitors with its approach. Recent data updates have reaffirmed my original thoughts of their likelihood of success in several indications.
- 11/30/2021
|
ALX Oncology Falls After Updated Data For Solid Tumors Candidate
- ALX Oncology Holdings Inc (NASDAQ: ALXO) released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. One cohort included gastric/gastroesophageal junction cancer patients receiving evorpacept plus Roche Holdings AG's (OTC: RHHBY) Herceptin (trastuzumab), plus chemotherapy.
- 11/09/2021
|
ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting
- SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the Company will be presenting early clinical data from ASPEN-02, its ongoing Phase 1/2 study evaluating evorpacept in combination with azacitidine for the treatment of myelodysplastic syndromes (“MDS”) in a poster presentation at the 63rd American Society of Hematology (“ASH”) Annual Meeting held December 11-14, 2021 in Atlanta, Georgia.
- 11/04/2021
|
ALX Oncology Announces Upcoming Virtual Investor Conference Participation
- SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in four upcoming virtual investor conferences.
- 11/02/2021
|
ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio
- SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company, and ScalmiBio, Inc. (“ScalmiBio”) announced today that ALX Oncology has acquired ScalmiBio.
- 10/07/2021
|
ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma
- -- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer Center -- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer Center
- 09/16/2021
|
ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space
- ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space
- 09/08/2021
|
ALX Oncology Announces Upcoming Virtual Investor Conference Participation
- BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences.
- 09/07/2021
|
The 3 Best Biotech Stocks to Buy Right Now
- Let your portfolio reflect your personality.
- 08/27/2021
|
So What's Going On With ALX Oncology's Stock?
- ALX Oncology Holdings Inc (NASDAQ: ALXO) shares are trading higher by 19.3% at $74.69, potentially in sympathy with Trillium Therapeutics which announced an acquisition by Pfizer Monday. ALX Oncology is a clinical-stage immuno-oncology company.
- 08/23/2021
|
ALX Oncology Shares Increase Over 25% Pre-Market: Why It Happened
- The shares of ALX Oncology Holdings Inc (NASDAQ: ALXO) increased by over 25% pre-market. This is why it happened.
- 08/23/2021
|
ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
- BURLINGAME, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the second quarter ended June 30, 2021 and provided clinical development and operational highlights.
- 08/12/2021
|
This Biotech Stock Is Too Cheap to Ignore
- Wall Street's short attention span has created an attractive entry point in this once-loved biotech.
- 07/29/2021
|
ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
- The second of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated The second of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated
- 07/28/2021
|
ALX Oncology (ALXO) Sees Hammer Chart Pattern: Time to Buy?
- ALX Oncology (ALXO) has been struggling lately, but the selling pressure may be coming to an end soon.
- 07/12/2021
|
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
- Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the biggest biopharma movers Tuesday. Odonate Gains On Institutional Stake: Shares of Odonate, a biopharma which recently announced discontinuation of development of an oral chemotherapy candidate named tesetaxel, are seeing renewed buying following disclosure of institutional stake.
- 07/06/2021
|
ALX Oncology Shares Jump As ALX148 Shows ORR of 72% In Patients With HER2 Positive Stomach Cancer
- ALX Oncology Holdings Inc (NASDAQ: ALXO) announced updated data from its ongoing ASPEN-01 Phase 1b trial evaluating ALX148 in combination with trastuzumab and chemotherapy to treat gastric or gastroesophageal junction cancer (GC). The new data were shared at the World Congress on Gastrointestinal Cancer.
- 07/06/2021
|
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer
- -- ORR of 72% Observed in Patients with > 2L HER2 Positive Gastric or Gastroesophageal Junction Cancer -- Estimated OS at 12 months of 76% -- ALX Oncology to Host Conference Call on July 6 th at 8:30 a.m. ET
- 07/03/2021
|
ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies
- --Interim report completed by ALX for a standard ongoing non-clinical safety study
- 06/14/2021
|
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer
- Randomized Phase 2/3 Study is Planned Based on Promising Results from the ASPEN-01 Phase 1b Trial in Gastric Cancer Patients Randomized Phase 2/3 Study is Planned Based on Promising Results from the ASPEN-01 Phase 1b Trial in Gastric Cancer Patients
- 06/10/2021
|
ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
- - The first of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated
- 05/10/2021
|
ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer
- Updated results will be presented from ASPEN-01, the ongoing Phase 1b Study of ALX148 in combination trastuzumab, ramucirumab and paclitaxel in patients with gastric or gastroesophageal junction cancer Updated results will be presented from ASPEN-01, the ongoing Phase 1b Study of ALX148 in combination trastuzumab, ramucirumab and paclitaxel in patients with gastric or gastroesophageal junction cancer
- 04/21/2021
|
ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148
- BURLINGAME, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announces that the post-grant review period for granted U.S. Patent No. 10,696,730 ended on March 30, 2021. This patent covers the lead product candidate ALX148, a next generation CD47-blocking therapeutic that combines a high-affinity signal regulatory protein-alpha (“SIRP“) CD47-binding domain fused with an inactivated, proprietary Fc domain. The U.S. patent is not expected to expire before August 5, 2036, excluding patent term adjustments or extensions.
- 04/05/2021
|
Top Wall Street analysts bet on these stocks for long-term growth
- TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Alcon, Semtech, Upstart, and others.
- 03/28/2021
|
ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones
- BURLINGAME, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided clinical development and operational highlights.
- 03/18/2021
|
ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics
- BURLINGAME, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Tallac Therapeutics, Inc. (“Tallac”), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced a collaboration to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics. Under the terms of the agreement, ALX Oncology and Tallac will share equally in the cost of research and development and any profits or losses incurred.
- 03/04/2021
|
Why Earnings Season Could Be Great for ALX Oncology (ALXO)
- ALX Oncology (ALXO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 03/03/2021
|
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021
- BURLINGAME, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2021.
- 01/11/2021
|
ALX Oncology: Targeting The CD47 Receptor For Cancers
- ALXO is a South Korea origin oncology concern valued at $3 billion on just phase 1 data. They have just a single asset, a CD47 blocker with some special differences.
- 01/08/2021
|
ALX Oncology: All Their Eggs In The Proverbial Basket
- ALX Oncology is developing a drug that encourages macrophages to "eat" targeted cancer cells. Since releasing an IPO in Summer 2020, their share price has more than tripled, despite only having a single drug in their pipeline.
- 01/07/2021
|
ALX Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference
- BURLINGAME, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 at 10:50 am ET.
- 01/05/2021
|
Notable Insider Buys of the Past Week: Mylan, Sonabank, Steak 'n Shake, U-Haul And More
- Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as has been the case as new COVID-19 cases surge.
- 12/20/2020
|
ALX Oncology Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- BURLINGAME, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the closing of its previously announced underwritten public offering of 2,737,000 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 357,000 additional shares of its common stock, at a price to the public of $76.00 per share. The aggregate gross proceeds to ALX Oncology from the offering were approximately $208.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by ALX Oncology.
- 12/14/2020
|
ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock
- BURLINGAME, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the pricing of an upsized underwritten public offering of 2,380,000 shares of its common stock at a price of $76.00 per share. All of the shares of common stock are being offered by ALX Oncology. The gross proceeds to ALX Oncology from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by ALX Oncology, are expected to be approximately $180.9 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on December 14, 2020, subject to the satisfaction of customary closing conditions. In addition, ALX Oncology has granted the underwriters a 30-day option to purchase up to an additional 357,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
- 12/09/2020
|
The Daily Biotech Pulse: CureVac Close To Coronavirus Vaccine Deal With EU, Entera Bio's Positive Readout, Patent Protection For Co-Diagnostics
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
- 08/20/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
U.S. IPO Week Ahead: The IPO Market Takes A Breather In A 3-IPO Week
- After an active July, the US IPO market is taking a breather. Three companies are scheduled to raise $2.5 billion in the week ahead, led by Chinese real estate giant KE Holdings.
- 08/08/2020
|
Stocks To Watch: Barrick Gold, Hedge Fund Reveals And Election Plays (NASDAQ:ACIA)
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 08/08/2020
|
The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...
- 08/05/2020
|
The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
ABIOMED, Inc. (NASDAQ: ABMD)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Annexon Inc (NASDAQ: ANNX)
Atossa...
- 08/04/2020
|
Lowest Insider Activity Since January - The Most Important Insider News (July 2020 Update)
- Insider activity is very informative to follow as insiders know their company better than anyone else.
- 08/03/2020
|
ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- BURLINGAME, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the closing of its initial public offering of 9,775,000 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 1,275,000 additional shares of common stock, at a public offering price of $19.00 per share. The aggregate gross proceeds to ALX Oncology from the offering were approximately $185.7 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by ALX Oncology. ALX Oncology’s common stock began trading on The Nasdaq Global Select Market on July 17, 2020 under the ticker symbol "ALXO."Jefferies, Credit Suisse, Piper Sandler and Cantor acted as joint book-running managers for the offering. LifeSci Capital acted as lead manager for the offering.Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on July 16, 2020. The offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@Jefferies.com; Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at usa.prospectus@credit-suisse.com; Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924, or by email at prospectus@psc.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor New York, New York 10022, or by email at prospectus@cantor.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About ALX OncologyALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to advance ALX148 into clinical development for the treatment of myelodysplastic syndromes and to continue clinical development for the treatment of a range of solid tumor indications. CONTACT: Media Contact Karen Sharma MacDougall (781) 235-3060 alx@macbiocom.com Investor Contact Peter Garcia CFO, ALX Oncology (650) 466-7125 Ext. 113 peter@alxoncology.com
- 07/21/2020
|
Applied DNA's COVID-19 Vaccine, And Other News: The Good, Bad And Ugly Of Biopharma
- Applied DNA reports positive preclinical results for COVID-19 vaccine. Berkeley Lights shows impressive debut on NASDAQ.
- 07/20/2020
|
U.S. IPO Weekly Recap: nCino Pops 195% In 8-IPO Week
- Eight IPOs and six SPACs entered public markets this past week, led by nCino, which soared 195% in the biggest first-day pop for a US tech company in nearly 20 years.
- 07/18/2020
|
Berkeley Lights IPO Jumps By Triple Digits As Hot Biotech Begins Trading
- Biotech company Berkeley Lights stock soared as trading began Friday with an initial public offering that drew heightened interest from institutional investors. It raised $178.2 million.
- 07/17/2020
|
IPO Update: ALX Oncology Seeks $128 Million IPO
- ALX Oncology has filed proposed terms for its $128 million IPO. The firm is developing treatments for blood and solid tumor cancers.
- 07/13/2020
|
U.S. IPO Week Ahead: GoHealth Takes The Lead In A 4-IPO Week
- Four IPOs and one SPAC plan to raise $1.5 billion in the week ahead, led by health insurance marketplace GoHealth.
- 07/11/2020
|
ALX Oncology Holdings Launches IPO Plan
- ALX Oncology has filed to raise $100 million in an IPO, although the final figure may differ. The company is advancing its ALX148 drug through trials for variou
- 07/01/2020
|
U.S. IPO Weekly Recap: Agora Pops 153% While Albertsons Falls Flat In A 6 IPO Week
- Six IPOs raised a combined $1.7 billion this past week. API platform Agora skyrocketed 153% in the best first day pop since 2019 IPO Beyond Meat. Albertsons fin
- 06/27/2020
|
